The automated and closed cell therapy processing systems market size has grown rapidly in recent years. It will grow from $1.53 billion in 2025 to $1.8 billion in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to manual cell processing methods, high contamination risks, limited workflow automation, reliance on traditional bioreactors, slow adoption of regenerative therapies.
The automated and closed cell therapy processing systems market size is expected to see rapid growth in the next few years. It will grow to $3.34 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to development of integrated closed-system platforms, advancements in robotics and microfluidics, growth of cell and gene therapy pipelines, rising regulatory compliance standards, increasing contract manufacturing organizations (cramos) for cell therapies. Major trends in the forecast period include increasing adoption of single-use and closed systems, rising demand for automated cell therapy workflows, focus on minimizing contamination and enhancing safety, integration of multi-step cell processing platforms, expansion of regenerative medicine and oncology applications.
The increasing demand for personalized medicine is anticipated to drive the growth of the automated and closed-cell therapy processing systems market in the coming years. Personalized medicine involves medical treatments customized to an individual’s genetic, molecular, or cellular profile to enhance effectiveness and reduce adverse effects. This rising demand is fueled by stronger regulatory frameworks and incentives that favor the approval of targeted and curative therapies over broadly used drugs. Automated and closed-cell therapy processing systems facilitate personalized medicine by allowing manufacturers to produce consistent, high-quality, patient-specific cell therapies that comply with stringent regulatory requirements. For example, in May 2025, according to the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 18 new personalized medicines in 2024, including six gene- or cell-based therapies, accounting for approximately 38 percent of all new molecular entities. As a result, the increasing demand for personalized medicine is propelling the growth of the automated and closed-cell therapy processing systems market.
Leading companies in this market are focusing on technological innovations, such as advanced cell preparation platforms, to enhance efficiency and maintain quality in cell therapy manufacturing. These platforms are automated systems designed to isolate, process, and prepare cells efficiently for clinical use or further analysis while reducing manual labor and contamination risks. In October 2024, Sino-Biocan Biotechnology Ltd., a China-based biotech company, launched the WUKONG Automated, Closed, Integrated Cell Processing System. This fully automated, closed platform streamlines the entire workflow from blood collection to cell culture and final filling. It is intended for hospitals, pharmaceutical R&D teams, and contract development and manufacturing organizations, offering improved efficiency, reduced contamination risks, and GMP-grade consistency through intelligent controls and real-time monitoring.
In March 2024, Donaldson Company Inc., a US-based filtration company, acquired Univercells Technologies for $157.28 million (€136 million). This acquisition strengthens Donaldson’s capabilities in life sciences by integrating Univercells Technologies’ automated and closed biomanufacturing platforms to provide end-to-end solutions for cell and gene therapy production. Univercells Technologies is a Belgium-based provider of automated and closed cell therapy processing systems.
Major companies operating in the automated and closed cell therapy processing systems market are Thermo Fisher Scientific Inc., Fresenius SE & Co. KGaA, Danaher Corporation, Merck KGaA, Parker Hannifin Corp., Corning Incorporated, Kawasaki Heavy Industries Ltd., Dover Corporation, Lonza Group AG, Terumo Corporation, Sartorius AG, Charles River Laboratories International Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Hamilton Company, Repligen Corporation, Cellares Inc., Ori Biotech Ltd., Autolus Therapeutics Plc.
North America was the largest region in the automated and closed cell therapy processing systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the automated and closed cell therapy processing systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the automated and closed cell therapy processing systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the automated and closed cell therapy processing systems market by increasing the cost of imported hardware components, bioreactors, and single-use consumables. Segments such as robotics, microfluidics devices, and sterile consumables are most impacted, with regions like North America and Asia-Pacific experiencing higher import costs. This has led to elevated production and operational expenses. On the positive side, tariffs have encouraged local manufacturing investments, innovation in domestic solutions, and diversification of the global supply chain to reduce dependency on imports.
The automated and closed cell therapy processing systems market research report is one of a series of new reports that provides automated and closed cell therapy processing systems market statistics, including automated and closed cell therapy processing systems industry global market size, regional shares, competitors with a automated and closed cell therapy processing systems market share, detailed automated and closed cell therapy processing systems market segments, market trends and opportunities, and any further data you may need to thrive in the automated and closed cell therapy processing systems industry. This automated and closed cell therapy processing systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Automated and closed cell therapy processing systems are integrated platforms designed to carry out multiple steps of cell therapy manufacturing within a sealed, controlled environment. These systems minimize manual handling, reducing contamination risks and ensuring the production of consistent, high-quality cell products. By automating processes such as cell isolation, expansion, and formulation, they enhance efficiency, reproducibility, and compliance with stringent regulatory standards.
The primary components of automated and closed cell therapy processing systems include software, hardware, and consumables. The software consists of specialized programs that control, monitor, and manage the sterile and precise manufacturing of cell-based therapies. These systems leverage technologies such as microfluidics, robotics, bioreactors, single-use technology, and three-dimensional (3D) cell culture. Key workflows include cryopreservation, separation, fill-finish, expansion, apheresis, and more. They are applied across fields such as oncology, regenerative medicine, autoimmune diseases, infectious diseases, and cardiovascular diseases, serving end users including pharmaceutical and biotechnology companies, research institutes, contract manufacturing organizations, and hospitals.
The automated and closed cell therapy processing systems market includes revenues earned by entities by providing services such as cell separation and isolation, quality control integration, genetic modification, and cell activation. The market value includes the value of related goods sold by the service provider or included within the service offering. The automated and closed cell therapy processing systems market also includes sales of control systems, single-use consumables, automated cell washing systems, and closed-system fluid handling components. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The automated and closed cell therapy processing systems market size is expected to see rapid growth in the next few years. It will grow to $3.34 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to development of integrated closed-system platforms, advancements in robotics and microfluidics, growth of cell and gene therapy pipelines, rising regulatory compliance standards, increasing contract manufacturing organizations (cramos) for cell therapies. Major trends in the forecast period include increasing adoption of single-use and closed systems, rising demand for automated cell therapy workflows, focus on minimizing contamination and enhancing safety, integration of multi-step cell processing platforms, expansion of regenerative medicine and oncology applications.
The increasing demand for personalized medicine is anticipated to drive the growth of the automated and closed-cell therapy processing systems market in the coming years. Personalized medicine involves medical treatments customized to an individual’s genetic, molecular, or cellular profile to enhance effectiveness and reduce adverse effects. This rising demand is fueled by stronger regulatory frameworks and incentives that favor the approval of targeted and curative therapies over broadly used drugs. Automated and closed-cell therapy processing systems facilitate personalized medicine by allowing manufacturers to produce consistent, high-quality, patient-specific cell therapies that comply with stringent regulatory requirements. For example, in May 2025, according to the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 18 new personalized medicines in 2024, including six gene- or cell-based therapies, accounting for approximately 38 percent of all new molecular entities. As a result, the increasing demand for personalized medicine is propelling the growth of the automated and closed-cell therapy processing systems market.
Leading companies in this market are focusing on technological innovations, such as advanced cell preparation platforms, to enhance efficiency and maintain quality in cell therapy manufacturing. These platforms are automated systems designed to isolate, process, and prepare cells efficiently for clinical use or further analysis while reducing manual labor and contamination risks. In October 2024, Sino-Biocan Biotechnology Ltd., a China-based biotech company, launched the WUKONG Automated, Closed, Integrated Cell Processing System. This fully automated, closed platform streamlines the entire workflow from blood collection to cell culture and final filling. It is intended for hospitals, pharmaceutical R&D teams, and contract development and manufacturing organizations, offering improved efficiency, reduced contamination risks, and GMP-grade consistency through intelligent controls and real-time monitoring.
In March 2024, Donaldson Company Inc., a US-based filtration company, acquired Univercells Technologies for $157.28 million (€136 million). This acquisition strengthens Donaldson’s capabilities in life sciences by integrating Univercells Technologies’ automated and closed biomanufacturing platforms to provide end-to-end solutions for cell and gene therapy production. Univercells Technologies is a Belgium-based provider of automated and closed cell therapy processing systems.
Major companies operating in the automated and closed cell therapy processing systems market are Thermo Fisher Scientific Inc., Fresenius SE & Co. KGaA, Danaher Corporation, Merck KGaA, Parker Hannifin Corp., Corning Incorporated, Kawasaki Heavy Industries Ltd., Dover Corporation, Lonza Group AG, Terumo Corporation, Sartorius AG, Charles River Laboratories International Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Hamilton Company, Repligen Corporation, Cellares Inc., Ori Biotech Ltd., Autolus Therapeutics Plc.
North America was the largest region in the automated and closed cell therapy processing systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the automated and closed cell therapy processing systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the automated and closed cell therapy processing systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the automated and closed cell therapy processing systems market by increasing the cost of imported hardware components, bioreactors, and single-use consumables. Segments such as robotics, microfluidics devices, and sterile consumables are most impacted, with regions like North America and Asia-Pacific experiencing higher import costs. This has led to elevated production and operational expenses. On the positive side, tariffs have encouraged local manufacturing investments, innovation in domestic solutions, and diversification of the global supply chain to reduce dependency on imports.
The automated and closed cell therapy processing systems market research report is one of a series of new reports that provides automated and closed cell therapy processing systems market statistics, including automated and closed cell therapy processing systems industry global market size, regional shares, competitors with a automated and closed cell therapy processing systems market share, detailed automated and closed cell therapy processing systems market segments, market trends and opportunities, and any further data you may need to thrive in the automated and closed cell therapy processing systems industry. This automated and closed cell therapy processing systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Automated and closed cell therapy processing systems are integrated platforms designed to carry out multiple steps of cell therapy manufacturing within a sealed, controlled environment. These systems minimize manual handling, reducing contamination risks and ensuring the production of consistent, high-quality cell products. By automating processes such as cell isolation, expansion, and formulation, they enhance efficiency, reproducibility, and compliance with stringent regulatory standards.
The primary components of automated and closed cell therapy processing systems include software, hardware, and consumables. The software consists of specialized programs that control, monitor, and manage the sterile and precise manufacturing of cell-based therapies. These systems leverage technologies such as microfluidics, robotics, bioreactors, single-use technology, and three-dimensional (3D) cell culture. Key workflows include cryopreservation, separation, fill-finish, expansion, apheresis, and more. They are applied across fields such as oncology, regenerative medicine, autoimmune diseases, infectious diseases, and cardiovascular diseases, serving end users including pharmaceutical and biotechnology companies, research institutes, contract manufacturing organizations, and hospitals.
The automated and closed cell therapy processing systems market includes revenues earned by entities by providing services such as cell separation and isolation, quality control integration, genetic modification, and cell activation. The market value includes the value of related goods sold by the service provider or included within the service offering. The automated and closed cell therapy processing systems market also includes sales of control systems, single-use consumables, automated cell washing systems, and closed-system fluid handling components. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Automated and Closed Cell Therapy Processing Systems Market Characteristics
3. Automated and Closed Cell Therapy Processing Systems Market Supply Chain Analysis
4. Global Automated and Closed Cell Therapy Processing Systems Market Trends and Strategies
5. Automated and Closed Cell Therapy Processing Systems Market Analysis of End Use Industries
7. Global Automated and Closed Cell Therapy Processing Systems Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Automated and Closed Cell Therapy Processing Systems Total Addressable Market (TAM) Analysis for the Market
9. Automated and Closed Cell Therapy Processing Systems Market Segmentation
10. Automated and Closed Cell Therapy Processing Systems Market Regional and Country Analysis
11. Asia-Pacific Automated and Closed Cell Therapy Processing Systems Market
12. China Automated and Closed Cell Therapy Processing Systems Market
13. India Automated and Closed Cell Therapy Processing Systems Market
14. Japan Automated and Closed Cell Therapy Processing Systems Market
15. Australia Automated and Closed Cell Therapy Processing Systems Market
16. Indonesia Automated and Closed Cell Therapy Processing Systems Market
17. South Korea Automated and Closed Cell Therapy Processing Systems Market
18. Taiwan Automated and Closed Cell Therapy Processing Systems Market
19. South East Asia Automated and Closed Cell Therapy Processing Systems Market
20. Western Europe Automated and Closed Cell Therapy Processing Systems Market
21. UK Automated and Closed Cell Therapy Processing Systems Market
22. Germany Automated and Closed Cell Therapy Processing Systems Market
23. France Automated and Closed Cell Therapy Processing Systems Market
24. Italy Automated and Closed Cell Therapy Processing Systems Market
25. Spain Automated and Closed Cell Therapy Processing Systems Market
26. Eastern Europe Automated and Closed Cell Therapy Processing Systems Market
27. Russia Automated and Closed Cell Therapy Processing Systems Market
28. North America Automated and Closed Cell Therapy Processing Systems Market
29. USA Automated and Closed Cell Therapy Processing Systems Market
30. Canada Automated and Closed Cell Therapy Processing Systems Market
31. South America Automated and Closed Cell Therapy Processing Systems Market
32. Brazil Automated and Closed Cell Therapy Processing Systems Market
33. Middle East Automated and Closed Cell Therapy Processing Systems Market
34. Africa Automated and Closed Cell Therapy Processing Systems Market
36. Automated and Closed Cell Therapy Processing Systems Market Competitive Landscape and Company Profiles
37. Automated and Closed Cell Therapy Processing Systems Market Other Major and Innovative Companies
40. Automated and Closed Cell Therapy Processing Systems Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Automated And Closed Cell Therapy Processing Systems Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses automated and closed cell therapy processing systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for automated and closed cell therapy processing systems? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The automated and closed cell therapy processing systems market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Component: Software; Hardware; Consumables2) By Technology: Microfluidics; Robotics; Bioreactors; Single-Use Technology; Three-Dimensional (3D) Cell Culture
3) By Workflow: Cryopreservation; Separation; Fill-Finish; Expansion; Apheresis; Other Workflows
4) By Application: Oncology; Regenerative Medicine; Autoimmune Diseases; Infectious Diseases; Cardiovascular Diseases
5) By End User: Pharmaceutical Companies; Biotechnology Companies; Research Institutes; Contract Manufacturing Organizations; Hospitals
Subsegments:
1) By Software: Process Control Software; Data Management Software; Quality Monitoring Software; Workflow Automation Software; Integration Software2) By Hardware: Cell Separation Devices; Bioreactors; Fluid Handling Systems; Centrifuges; Tubing And Connectors
3) By Consumables: Sterile Bags; Culture Media; Reagents And Buffers; Filters And Cartridges; Single-Use Tubing Sets
Companies Mentioned: Thermo Fisher Scientific Inc.; Fresenius SE & Co. KGaA; Danaher Corporation; Merck KGaA; Parker Hannifin Corp.; Corning Incorporated; Kawasaki Heavy Industries Ltd.; Dover Corporation; Lonza Group AG; Terumo Corporation; Sartorius AG; Charles River Laboratories International Inc.; Beckman Coulter Inc.; Bio-Rad Laboratories Inc.; STEMCELL Technologies Inc.; Miltenyi Biotec B.V. & Co. KG; Hamilton Company; Repligen Corporation; Cellares Inc.; Ori Biotech Ltd.; Autolus Therapeutics Plc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Automated and Closed Cell Therapy Processing Systems market report include:- Thermo Fisher Scientific Inc.
- Fresenius SE & Co. KGaA
- Danaher Corporation
- Merck KGaA
- Parker Hannifin Corp.
- Corning Incorporated
- Kawasaki Heavy Industries Ltd.
- Dover Corporation
- Lonza Group AG
- Terumo Corporation
- Sartorius AG
- Charles River Laboratories International Inc.
- Beckman Coulter Inc.
- Bio-Rad Laboratories Inc.
- STEMCELL Technologies Inc.
- Miltenyi Biotec B.V. & Co. KG
- Hamilton Company
- Repligen Corporation
- Cellares Inc.
- Ori Biotech Ltd.
- Autolus Therapeutics Plc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.8 Billion |
| Forecasted Market Value ( USD | $ 3.34 Billion |
| Compound Annual Growth Rate | 16.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
